Assay Detail
Functional
CHEMBL5336368
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in Vero E6 cells assessed as reduction in viral replication incubated for 3 days by viral plaque assay
7
Total Activities
7
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Severe acute respiratory syndrome coronavirus 2 |
| Cell Type | Vero C1008 |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Target
SARS-CoV-2 (CHEMBL4303835) ↗| Type | ORGANISM |
| Organism | Severe acute respiratory syndrome coronavirus 2 |
Publication
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| EC50 | 7 | 5.77 | 6.24 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4868443 | — | — | 1 | 6.24 |
| CHEMBL4860690 | — | — | 1 | 6.16 |
| CHEMBL4856219 | — | — | 1 | 6.10 |
| CHEMBL4850660 | — | — | 1 | 5.92 |
| CHEMBL5287345 | — | — | 1 | 5.69 |
| CHEMBL3427167 | — | — | 1 | 5.34 |
| CHEMBL5283903 | — | — | 1 | 4.96 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4868443 | — | EC50 | = | 570.0 | nM | 6.24 |
| CHEMBL4860690 | — | EC50 | = | 700.0 | nM | 6.16 |
| CHEMBL4856219 | — | EC50 | = | 800.0 | nM | 6.10 |
| CHEMBL4850660 | — | EC50 | = | 1200.0 | nM | 5.92 |
| CHEMBL5287345 | — | EC50 | = | 2060.0 | nM | 5.69 |
| CHEMBL3427167 | — | EC50 | = | 4610.0 | nM | 5.34 |
| CHEMBL5283903 | — | EC50 | = | 11100.0 | nM | 4.96 |